Referências
Principais artigos
Bain BJ, Daniel Y, Henthorn J, et al. Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology guideline. Br J Haematol. 2023 Jun;201(6):1047-65.Texto completo Resumo
National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014. Sep 2014 [internet publication].Texto completo
DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020 Apr 28;4(8):1554-88.Texto completo Resumo
Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020 Jan 28;4(2):327-55.Texto completo Resumo
Trompeter S, Massey E, Robinson S, et al. Position paper on International Collaboration for Transfusion Medicine (ICTM) Guideline 'Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline'. Br J Haematol. 2020 May;189(3):424-27.Texto completo Resumo
Artigos de referência
1. Pass KA, Lane PA, Fernhoff PM, et al. US newborn screening system guidelines II: follow-up of children, diagnosis, management, and evaluation. Statement of the Council of Regional Networks for Genetic Services (CORN). J Pediatr. 2000 Oct;137(suppl 4):S1-46. Resumo
2. Dormandy E, James J, Inusa B, et al. How many people have sickle cell disease in the UK? J Public Health (Oxf). 2018 Sep 1;40(3):e291-5.Texto completo Resumo
3. National Health Service (UK). NHS sickle cell and thalassaemia (SCT) screening programme. Oct 2023 [internet publication].Texto completo
4. Centers for Disease Control and Prevention (CDC). Data and statistics on sickle cell disease. May 2024 [internet publication].Texto completo
5. Piel FB, Hay SI, Gupta S, et al. Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions. PLoS Med. 2013;10(7):e1001484.Texto completo Resumo
6. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013 Jan 12;381(9861):142-51.Texto completo Resumo
7. GBD 2021 Sickle Cell Disease Collaborators. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the Global Burden of Disease Study 2021. Lancet Haematol. 2023 Aug;10(8):e585-99.Texto completo Resumo
8. Sundd P, Gladwin MT, Novelli EM. Pathophysiology of sickle cell disease. Annu Rev Pathol. 2019 Jan 24;14:263-92.Texto completo Resumo
9. Piel FB, Steinberg MH, Rees DC. Sickle cell disease. N Engl J Med. 2017 Apr 20;376(16):1561-73.Texto completo Resumo
10. Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest. 1980 Jan;65(1):154-60.Texto completo Resumo
11. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy. Microcirculation. 2004 Mar;11(2):129-51. Resumo
12. Yale SH, Nagib N, Guthrie T. Approach to the vaso-occlusive crisis in adults with sickle cell disease. Am Fam Physician. 2000 Mar 1;61(5):1349-56, 1363-4. Resumo
13. Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol. 2007 Apr-May;24(3):159-70.Texto completo Resumo
14. Naik RP, Smith-Whitley K, Hassell KL, et al. Clinical outcomes associated with sickle cell trait: a systematic review. Ann Intern Med. 2018 Nov 6;169(9):619-27.Texto completo Resumo
15. Bain BJ, Daniel Y, Henthorn J, et al. Significant haemoglobinopathies: a guideline for screening and diagnosis: a British Society for Haematology guideline. Br J Haematol. 2023 Jun;201(6):1047-65.Texto completo Resumo
16. The American College of Obstetricians and Gynecologists. ACOG practice advisory: hemoglobinopathies in pregnancy. Aug 2022 [internet publication].Texto completo
17. The American College of Obstetricians and Gynecologists. Committee opinion no. 690: carrier screening in the age of genomic medicine. Mar 2017 [internet publication].Texto completo Resumo
18. American College of Obstetricians and Gynecologists. Committee opinion no. 691: carrier screening for genetic conditions. Mar 2017 [internet publication].Texto completo Resumo
19. Dormandy E, Gulliford M, Bryan S, et al. Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. 2010 Oct 5;341:c5132.Texto completo Resumo
20. American College of Obstetricians and Gynecologists. Hemoglobinopathies in pregnancy: practice bulletin no. 78. Mar 2007 [internet publication].Texto completo
21. Gov.UK. Counselling and referral for prenatal diagnosis (PND).Apr 2025 [internet publication].Texto completo
22. Health Resources & Services Administration. Recommended uniform screening panel. Jan 2023 [internet publication].Texto completo
23. Health Resources & Services Administration. Advisory committee on heritable disorders in newborns and children. [internet publication].Texto completo
24. Centers for Disease Control and Prevention. About newborn screening. Dec 2024 [internet publication].Texto completo
25. Association of Public Health Laboratories. Hemoglobinopathies: current practices for screening, confirmation and follow-up. Jun 2025 [internet publication].Texto completo
26. Quarmyne MO, Bock F, Lakshmanan S, et al. Newborn screening for sickle cell disease and thalassemia. JAMA Health Forum. 2025 Mar 7;6(3):e250064.Texto completo Resumo
27. van Campen JC, Sollars ESA, Thomas RC, et al. Next generation sequencing in newborn screening in the United Kingdom National Health Service. Int J Neonatal Screen. 2019 Dec;5(4):40.Texto completo Resumo
28. Watson MS, Lloyd-Puryear MA, Howell RR. The progress and future of US newborn screening. Int J Neonatal Screen. 2022 Jul 18;8(3):41.Texto completo Resumo
29. NHS England. Newborn blood spot screening: programme handbook. Apr 2025 [internet publication].Texto completo
30. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Resumo
31. Gill FM, Sleeper LA, Weiner SJ, et al; Cooperative Study of Sickle Cell Disease. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood. 1995 Jul 15;86(2):776-83.Texto completo Resumo
32. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 2000 Jan 13;342(2):83-9.Texto completo Resumo
33. Gualandro SF, Fonseca GH, Yokomizo IK, et al. Cohort study of adult patients with haemoglobin SC disease: clinical characteristics and predictors of mortality. Br J Haematol. 2015 Nov;171(4):631-7.Texto completo Resumo
34. Mukisi-Mukaza M, Elbaz A, Samuel-Leborgne Y, et al. Prevalence, clinical features, and risk factors of osteonecrosis of the femoral head among adults with sickle cell disease. Orthopedics. 2000 Apr;23(4):357-63. Resumo
35. Vosmaer A, Pereira RR, Koenderman JS, et al. Coagulation abnormalities in Legg-Calvé-Perthes disease. J Bone Joint Surg Am. 2010 Jan;92(1):121-8. Resumo
36. Public Health England. Sickle cell and thalassaemia (SCT) screening: programme overview. Aug 2023 [internet publication].Texto completo
37. Asnani MR, Quimby KR, Bennett NR, et al. Interventions for patients and caregivers to improve knowledge of sickle cell disease and recognition of its related complications. Cochrane Database Syst Rev. 2016 Oct 6;(10):CD011175.Texto completo Resumo
38. National Heart, Lung, and Blood Institute. Evidence-based management of sickle cell disease: expert panel report, 2014. Sep 2014 [internet publication].Texto completo
39. Rankine-Mullings AE, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2021 Mar 8;(3):CD003427.Texto completo Resumo
40. Dekker LH, Fijnvandraat K, Brabin BJ, et al. Micronutrients and sickle cell disease, effects on growth, infection and vaso-occlusive crisis: a systematic review. Pediatr Blood Cancer. 2012 Aug;59(2):211-5. Resumo
41. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44.Texto completo Resumo
42. Redwood AM, Williams EM, Desai P, et al. Climate and painful crisis of sickle-cell disease in Jamaica. BMJ. 1976 Jan 10;1(6001):66-8.Texto completo Resumo
43. Mohan J, Marshall JM, Reid HL, et al. Peripheral vascular response to mild indirect cooling in patients with homozygous sickle cell (SS) disease and the frequency of painful crisis. Clin Sci (Lond). 1998 Feb;94(2):111-20. Resumo
44. Beutler E. Disorders of hemoglobin structure: sickle cell anemia and related abnormalities. In: Lichtman MA, Beutler E, Kaushansky K, et al, eds. Williams hematology. 7th ed. New York, NY: McGraw-Hill; 2006:667-700.
45. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995 May 18;332(20):1317-22.Texto completo Resumo
46. Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med. 2008 Jun 17;148(12):939-55.Texto completo Resumo
47. Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008 Mar;(165):1-95. Resumo
48. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005 Oct 1;106(7):2269-75.Texto completo Resumo
49. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996 Jun;128(6):820-8. Resumo
50. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr. 2002 Feb;140(2):225-9. Resumo
51. Wang WC, Ware RE, Miller ST, et al; BABY HUG investigators. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011 May 14;377(9778):1663-72.Texto completo Resumo
52. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood. 2004 Mar 15;103(6):2039-45.Texto completo Resumo
53. Rankine-Mullings AE, Nevitt SJ. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2022 Sep 1;9(9):CD002202.Texto completo Resumo
54. Ware RE, Helms RW; SWiTCH Investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012 Apr 26;119(17):3925-32.Texto completo Resumo
55. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999 Sep 1;94(5):1550-4.Texto completo Resumo
56. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 Apr 2;289(13):1645-51.Texto completo Resumo
57. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood. 2010 Mar 25;115(12):2354-63.Texto completo Resumo
58. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol. 2010 Jun;85(6):403-8.Texto completo Resumo
59. Cieri-Hutcherson NE, Hutcherson TC, Conway-Habes EE, et al. Systematic review of i-glutamine for prevention of vaso-occlusive pain crisis in patients with sickle cell disease. Pharmacotherapy. 2019 Nov;39(11):1095-1104. Resumo
60. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018 Jul 19;379(3):226-35. Resumo
61. Quinn CT. L-glutamine for sickle cell anemia: more questions than answers. Blood. 2018 Aug 16;132(7):689-93. Resumo
62. ClinicalTrials.gov. Study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients (STAND). ClinicalTrials.gov Identifier: NCT03814746. May 2024 [internet publication].Texto completo
63. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017 Feb 2;376(5):429-39.Texto completo Resumo
64. Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019 Jan;94(1):55-61.Texto completo Resumo
65. Han J, Saraf SL, Gordeuk VR. Systematic review of crizanlizumab: a new parenteral option to reduce vaso-occlusive pain crises in patients with sickle cell disease. Pharmacotherapy. 2020 Jun;40(6):535-43. Resumo
66. DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020 Apr 28;4(8):1554-88.Texto completo Resumo
67. Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 guideline for the primary prevention of stroke: a guideline from the American Heart Association/American Stroke Association. Stroke. 2024 Dec;55(12):e344-424.Texto completo Resumo
68. Lee MT, Piomelli S, Granger S, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood. 2006 Aug 1;108(3):847-52.Texto completo Resumo
69. Adams RJ, Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med. 2005 Dec 29;353(26):2769-78.Texto completo Resumo
70. Vichinsky EP, Haberkern CM, Neumayr L, et al; The Preoperative Transfusion in Sickle Cell Disease Study Group. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 1995 Jul 27;333(4):206-13.Texto completo Resumo
71. Estcourt LJ, Kimber C, Trivella M, et al. Preoperative blood transfusions for sickle cell disease. Cochrane Database Syst Rev. 2020 Jul 2;(7):CD003149.Texto completo Resumo
72. Howard J, Malfroy M, Llewelyn C, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013 Mar 16;381(9870):930-8. Resumo
73. Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion. 2018 Jun;58(6):1555-66. Resumo
74. Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020 Jan 28;4(2):327-55.Texto completo Resumo
75. Trompeter S, Massey E, Robinson S, et al. Position paper on International Collaboration for Transfusion Medicine (ICTM) Guideline 'Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline'. Br J Haematol. 2020 May;189(3):424-27.Texto completo Resumo
76. Fasano RM, Meyer EK, Branscomb J, et al. Impact of red blood cell antigen matching on alloimmunization and transfusion complications in patients with sickle cell disease: a systematic review. Transfus Med Rev. 2019 Jan;33(1):12-23. Resumo
77. Oteng-Ntim E, Pavord S, Howard R, et al. Management of sickle cell disease in pregnancy. A British Society for Haematology Guideline. Br J Haematol. 2021 Sep;194(6):980-95.Texto completo Resumo
78. Boafor TK, Olayemi E, Galadanci N, et al. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG. 2016 Apr;123(5):691-8. Resumo
79. Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis. Blood. 2015 Nov 19;126(21):2424-35.Texto completo Resumo
80. Food and Drug Administration (FDA). FDA is alerting patients and health care professionals about the voluntary withdrawal of Oxbryta from the market due to safety concerns. September 2024 [internet publication].Texto completo
81. European Medicines Agency (EMA). EMA recommends suspension of sickle cell disease medicine Oxbryta. September 2024 [internet publication].Texto completo
82. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020 Jun 23;4(12):2656-2701.Texto completo Resumo
83. Royal College of Emergency Medicine. Management of acute presentations of sickle cell disease. Mar 2024 [internet publication].Texto completo
84. Jacobson SJ, Kopecky EA, Joshi P, et al. Randomised trial of oral morphine for painful episodes of sickle-cell disease in children. Lancet. 1997 Nov 8;350(9088):1358-61. Resumo
85. Cooper TE, Hambleton IR, Ballas SK, et al. Pharmacological interventions for painful sickle cell vaso-occlusive crises in adults. Cochrane Database Syst Rev. 2019 Nov 14;2019(11):CD012187.Texto completo Resumo
86. Aboursheid T, Albaroudi O, Alahdab F. Inhaled nitric oxide for treating pain crises in people with sickle cell disease. Cochrane Database Syst Rev. 2019 Oct 11;(10):CD011808.Texto completo Resumo
87. Dampier CD, Wager CG, Harrison R, et al; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN). Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. Am J Hematol. 2012 Oct;87(10):E71-4.Texto completo Resumo
88. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000 Jun 22;342(25):1855-65.Texto completo Resumo
89. Dolatkhah R, Dastgiri S. Blood transfusions for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2020 Jan 16;(1):CD007843.Texto completo Resumo
90. Bundy DG, Richardson TE, Hall M, et al. Association of guideline-adherent antibiotic treatment with readmission of children with sickle cell disease hospitalized with acute chest syndrome. JAMA Pediatr. 2017 Nov 1;171(11):1090-9.Texto completo Resumo
91. Kanter J, Liem RI, Bernaudin F, et al. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation. Blood Adv. 2021 Sep 28;5(18):3668-89.Texto completo Resumo
92. Oringanje C, Nemecek E, Oniyangi O. Hematopoietic stem cell transplantation for people with sickle cell disease. Cochrane Database Syst Rev. 2020 Jul 3;(7):CD007001.Texto completo Resumo
93. Shenoy S, Angelucci E, Arnold SD, et al. Current results and future research priorities in late effects after hematopoietic stem cell transplantation for children with sickle cell disease and thalassemia: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Apr;23(4):552-61.Texto completo Resumo
94. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94-101. Resumo
95. Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev. 2015 May 8;(5):CD001916.Texto completo Resumo
96. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;1(1):CD007798.Texto completo Resumo
97. Martí-Carvajal AJ, Solà I, Agreda-Pérez LH. Treatment for avascular necrosis of bone in people with sickle cell disease. Cochrane Database Syst Rev. 2019 Dec 5;(12):CD004344.Texto completo Resumo
98. US Food and Drug Administration. FDA drug safety communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. Apr 2017 [internet publication].Texto completo
99. Medicines and Healthcare Products Regulatory Agency. Codeine: restricted use as analgesic in children and adolescents after European safety review. Jun 2013 [internet publication].Texto completo
100. European Medicines Agency. Restrictions on use of codeine for pain relief in children - CMDh endorses PRAC recommendation. Jun 2013 [internet publication].Texto completo
101. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia. N Engl J Med. 2021 Jan 21;384(3):252-60.Texto completo Resumo
102. ClinicalTrials.gov. A safety and efficacy study evaluating CTX001 in subjects with severe sickle cell disease. ClinicalTrials.gov ID: NCT03745287. Nov 2023 [internet publication].Texto completo
103. ClinicalTrials.gov. A long-term follow-up study in subjects who received CTX001. ClinicalTrials.gov ID: NCT04208529. Nov 2022 [internet publiction].Texto completo
104. ClinicalTrials.gov. Evaluation of safety and efficacy of CTX001 in pediatric participants with severe sickle cell disease (SCD). ClinicalTrials.gov ID: NCT05329649. Aug 2023 [internet publication].Texto completo
105. NHS England. Revolutionary gene-editing therapy for sickle cell ‘offers hope of a cure’ for NHS patients. Jan 2025 [internet publication].Texto completo
106. Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022 Feb 17;386(7):617-28.Texto completo Resumo
107. ClinicalTrials.gov. A study evaluating gene therapy with BB305 Lentiviral vector in sickle cell disease. ClinicalTrials.gov ID: NCT04293185. Sep 2023 [internet publication].Texto completo
108. McArthur JG, Svenstrup N, Chen C, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020 Mar; 105(3):623–31.Texto completo Resumo
109. U.S. National library of medicine. Clinical trials. A study of IMR-687 in subjects with sickle cell disease. Jul 2020 [internet publication].Texto completo
110. ClinicalTrials.gov. A study evaluating the efficacy and safety of Mitapivat (AG-348) in participants with sickle cell disease. ClinicalTrials.gov Identifier: NCT05031780. Mar 2022 [internet publication].Texto completo
111. Rab MAE, Van Oirschot BA, Kosinski PA, et al. AG-348 (Mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes. Haematologica. 2021 Jan 1;106(1):238-49.Texto completo Resumo
112. Jiao B, Johnson KM, Ramsey SD, et al. Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries. Blood Adv. 2023 Jul 11;7(13):3276-83.Texto completo Resumo
113. Elmariah H, Garrett ME, De Castro LM, et al. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol. 2014 May;89(5):530-5.Texto completo Resumo
114. Grosse SD, Odame I, Atrash HK, et al. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med. 2011 Dec;41(6 suppl 4):S398-405.Texto completo Resumo
115. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998 Jan 1;91(1):288-94.Texto completo Resumo
116. Estcourt LJ, Kohli R, Hopewell S, et al. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database Syst Rev. 2020 Jul 27;(7):CD003146.Texto completo Resumo
117. Estcourt LJ, Kimber C, Hopewell S, et al. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2020 Apr 6;(4):CD012389.Texto completo Resumo
118. Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018 Aug 1;(8):CD012082.Texto completo Resumo
119. Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016 Feb 13;387(10019):661-70.Texto completo Resumo
120. Miller ST, Jensen D, Rao SP. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident. J Pediatr. 1992 Jan;120(1):54-7. Resumo
121. Krauss JS, Freant LJ, Lee JR. Gastrointestinal pathology in sickle cell disease. Ann Clin Lab Sci. 1998 Jan-Feb;28(1):19-23. Resumo
122. Omata M, Johnson CS, Tong M, et al. Pathological spectrum of liver diseases in sickle cell disease. Dig Dis Sci. 1986 Mar;31(3):247-56. Resumo
123. Schubert TT. Hepatobiliary system in sickle cell disease. Gastroenterology. 1986 Jun;90(6):2013-21. Resumo
124. Seguier-Lipszyc E, de Lagausie P, Benkerrou M, et al. Elective laparoscopic cholecystectomy. Surg Endosc. 2001 Mar;15(3):301-4. Resumo
125. Bonatsos G, Birbas K, Toutouzas K, et al. Laparoscopic cholecystectomy in adults with sickle cell disease. Surg Endosc. 2001 Aug;15(8):816-9. Resumo
126. Owusu-Ofori S, Remmington T. Splenectomy versus conservative management for acute sequestration crises in people with sickle cell disease. Cochrane Database Syst Rev. 2017 Nov 7;(11):CD003425.Texto completo Resumo
127. Oligbu G, Fallaha M, Pay L, et al. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature. Br J Haematol. 2019 May;185(4):743-751.Texto completo Resumo
128. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003 Nov 15;327(7424):1151-5.Texto completo Resumo
129. Leitão Guerra RL, Leitão Guerra CL, Bastos MG, et al. Sickle cell retinopathy: What we now understand using optical coherence tomography angiography. A systematic review. Blood Rev. 2019 May;35:32-42. Resumo
130. Rodgers GP, Roy MS, Noguchi CT, et al. Is there a role for selective vasodilation in the management of sickle cell disease? Blood. 1988 Mar;71(3):597-602.Texto completo Resumo
131. Myint KT, Sahoo S, Thein AW, et al. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2015 Oct 9;(10):CD010790.Texto completo Resumo
132. Morgan AG. Sickle cell leg ulcers. Int J Dermatol. 1985 Dec;24(10):643-4. Resumo
133. Castro O, Gladwin MT. Pulmonary hypertension in sickle cell disease: mechanisms, diagnosis, and management. Hematol Oncol Clin North Am. 2005 Oct;19(5):881-96. Resumo
134. Liem RI, Lanzkron S, D Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019 Dec 10;3(23):3867-97.Texto completo Resumo
135. Klings ES, Machado RF, Barst RJ, et al.; American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014 Mar 15;189(6):727-40. Resumo
136. Machado RF, Martyr S, Kato GJ, et al. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol. 2005 Aug;130(3):445-53.Texto completo Resumo
137. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996 Feb 1;334(5):296-301.Texto completo Resumo
138. McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med. 1999 May 4;130(9):740-3. Resumo
139. Olaosebikan R, Ernest K, Bojang K, et al. A randomized trial to compare the safety, tolerability, and effectiveness of 3 antimalarial regimens for the prevention of malaria in Nigerian patients with sickle cell disease. J Infect Dis. 2015 Aug 15;212(4):617-25.Texto completo Resumo
140. Mantadakis E, Cavender JD, Rogers ZR, et al. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999 Nov-Dec;21(6):518-22. Resumo
141. Arduini GAO, Trovó de Marqui AB. Prevalence and characteristics of priapism in sickle cell disease. Hemoglobin. 2018 Mar;42(2):73-77. Resumo
142. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020 Apr 6;(4):CD004198.Texto completo Resumo
143. Phebus CK, Gloninger MF, Maciak BJ. Growth patterns by age and sex in children with sickle cell disease. J Pediatr. 1984 Jul;105(1):28-33. Resumo
144. Fung EB, Harmatz PR, Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion. 2008 Sep;48(9):1971-80. Resumo
145. Shah FT, Porter JB, Sadasivam N, et al. Guidelines for the monitoring and management of iron overload in patients with haemoglobinopathies and rare anaemias. Br J Haematol. 2022 Jan;196(2):336-50.Texto completo Resumo
146. Kwiatkowski JL, Hamdy M, El-Beshlawy A, et al. Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study. Blood Adv. 2022 Feb 22;6(4):1243-54.Texto completo Resumo
147. Meerpohl JJ, Schell LK, Rücker G, et al. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev. 2014 May 27;(5):CD007477.Texto completo Resumo
148. Sridharan K, Sivaramakrishnan G. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis. Expert Rev Clin Pharmacol. 2018 Jun;11(6):641-50. Resumo
149. Nelson DA, Deuster PA, Carter R 3rd, et al. Sickle cell trait, rhabdomyolysis, and mortality among U.S. Army Soldiers. N Engl J Med. 2016 Aug 4;375(5):435-42.Texto completo Resumo
150. Yates AM, Aygun B, Nuss R, et al. Health supervision for children and adolescents with sickle cell disease: clinical report. Pediatrics. 2024 Aug 1;154(2):e2024066842.Texto completo Resumo
151. Nguyen AT, Curtis KM, Tepper NK, et al. U.S. Medical eligibility criteria for contraceptive use, 2024. MMWR Recomm Rep. 2024 Aug 8;73(4):1-126.Texto completo Resumo
152. Leroy-Melamed M, McGann P, Van Doren L. How we approach contraception for adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2025 Jun;72(6):e31683. Resumo
153. Lottenberg R, Hassell KL. An evidence-based approach to the treatment of adults with sickle cell disease. Hematology Am Soc Hematol Educ Program. 2005:58-65.Texto completo Resumo
154. UK Health Security Agency. The Green Book: immunisation against infectious disease. Nov 2020 [internet publication].Texto completo
155. Centers for Disease Control and Prevention. Influenza (flu): ACIP recommendations summary. Sep 2024 [internet publication].Texto completo
O uso deste conteúdo está sujeito ao nosso aviso legal